Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UD TGFbi NK cells + temozolomide
- Development stage
- Unknown
- Lead developer
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Oral
01
Overview
UD TGFbi NK cells + temozolomide is an investigational combination immunotherapy regimen being evaluated for the treatment of stage IV melanoma, particularly cases with brain metastases. The regimen consists of allogeneic natural killer (NK) cells derived from universal donors (UD) that have been expanded ex-vivo and 'imprinted' to be insensitive to Transforming Growth Factor-beta (TGF-beta). TGF-beta is a potent immunosuppressive cytokine frequently found in the tumor microenvironment that typically inhibits NK cell function; by rendering these cells TGF-beta insensitive (TGFbi), their anti-tumor cytotoxic activity is preserved. Temozolomide, an oral alkylating agent, is administered as part of the protocol to serve as a lymphodepleting agent, creating a more favorable environment for the expansion and persistence of the infused NK cells, while also providing direct anti-neoplastic activity.
- Other names
- Universal Donor TGF-beta Imprinted Natural Killer CellsUD TGFbetai NK cellsEx-Vivo Expanded Allogeneic Universal Donor TGFbi NK Cells
02
Targets
DNA
Beyond the preview
Go deeper on UD TGFbi NK cells + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UD TGFbi NK cells + temozolomide.